ESR1 and breast cancer: As ER, PR and HER2 are the molecular biomarkers currently used in routine clinical practice to help treatment decision in breast cancer, the identification of miRNAs whose expression could be related to their status could help to discover new molecular alterations involved in this tumor type [16].